Candel Therapeutics (CADL)
(Delayed Data from NSDQ)
$6.70 USD
+0.19 (2.92%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $6.72 +0.02 (0.30%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CADL 6.70 +0.19(2.92%)
Will CADL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CADL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CADL
Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
Candel (CADL) Reports Upbeat Data From Lung Cancer Study
CADL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study
Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409
Other News for CADL
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
7 A-Rated Biotech Stocks Worth Betting on in June
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
Candel Therapeutics to Join Russell 3000? Index